The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Association of the 3'-untranslated region KRAS-variant with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Joanne B. Weidhaas
Employment or Leadership Position - Mira Dx (I,U)
Consultant or Advisory Role - Mira Dx (U)
Stock Ownership - Mira Dx (B)
Ju-Whei Lee
No relevant relationships to disclose
Robbert Slebos
No relevant relationships to disclose
Jason Howard
No relevant relationships to disclose
Jimena Perez
No relevant relationships to disclose
Jill Gilbert
No relevant relationships to disclose
Sunitha Nallur
No relevant relationships to disclose
Trupti Paranjape
No relevant relationships to disclose
Joaquin J. Garcia
No relevant relationships to disclose
Barbara Burtness
No relevant relationships to disclose
Arlene A. Forastiere
No relevant relationships to disclose
Christine H. Chung
No relevant relationships to disclose